2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

By Jose Luis Zamorano, P. Lancellotti, D. Rodríguez Muñoz, V. Aboyans, R. Asteggiano, M. Galderisi, G. Habib, D. Lenihan, Gregory Y. H. Lip, A. Lyon and 25 more. European Journal of Heart Failure, 2016

779 citations recorded by the source corpus.

No abstract available Keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance.

Subfields: Cardiology and Cardiovascular Medicine, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/129b66f12f8170070caa20ffce4ceac17b1975ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Baccarani
2. J. Cortes
3. H. Kantarjian
4. M. Deininger
5. A. Hochhaus
6. Brian J. Druker
7. G. Saglio
8. R. Larson

Citations in the corpus

• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020, methodology): “For any TKI, QTcF should be measured by electrocardiography prior to commencing and subsequently before using any other agent known to increase the QT interval [83, 84].”